From August 22 to 24, 2024, the 18th National Congress of Laboratory Medicine of the Chinese Medical Association (NCLM) was held in Hangzhou, along the scenic Qiantang River.
Organized by the Chinese Medical Association and its Laboratory Medicine Branch and hosted by the Zhejiang Medical Association, the conference focused on the latest research achievements, technological developments, and emerging trends in clinical laboratory medicine and laboratory management. It also provided a platform for in-depth discussions on the new challenges and opportunities facing the field.
Leading experts, renowned specialists, industry professionals, and more than 200 IVD companies gathered at the event to exchange knowledge, explore new developments, and share insights into the future of laboratory medicine. Medconn brought its latest HbA1c solutions and technological advancements to the conference, attracting strong interest and active engagement from attendees.
Event Highlights
Medconn's booth quickly became a focal point at the exhibition. The impressive MQ-8000 four-module HbA1c automation system, the MQ-3000, designed to support diagnostic needs in primary healthcare settings, and the internationally marketed MH-60 and MH-120 hematology analyzers attracted a large number of visitors for product consultations and technical exchanges.
Brand Highlights
As the global prevalence of diabetes continues to rise, HbA1c is playing an increasingly important role in the diagnosis and management of diabetes.
With more than a decade of expertise in HbA1c testing, Medconn is one of the pioneering Chinese manufacturers to independently develop HbA1c analysis systems based on high-performance liquid chromatography (HPLC). Thanks to its high sensitivity and stable performance, ion-exchange HPLC is widely recognized as a reference method for HbA1c testing.
Medconn's core MQ Series HbA1c Analysis Systems have established a strong position in the domestic market through outstanding product quality and technological innovation. Their growing industry recognition has further strengthened Medconn's reputation as a leading Chinese HbA1c solution provider.
Building on its strong reputation in China, Medconn has also achieved significant growth in international markets. Its expanding global presence and increasing brand recognition reflect the company's successful internationalization strategy and growing influence in the global diagnostics market.
Meanwhile, the MH-60 Compact 5-Part Differential Hematology Analyzer and MH-120 fully automated hematology analyzer continue to demonstrate Medconn's commitment to product innovation and advanced diagnostic technology. Designed to meet diverse clinical needs, these solutions have gained growing recognition in international markets.
As Medconn's global brand presence continues to expand, demand for its hematology products has increased significantly, with international orders continuing to grow. This strong market response further demonstrates the competitiveness and growing recognition of Medconn's diagnostic solutions worldwide.
